First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Michael Mark; Patrizia Froesch; Katrin Gysel; Sacha I. Rothschild; Alfredo Addeo; Christoph J. Ackermann; Sabrina Chiquet; Martina Schneider; Karin Ribi; Angela Fischer Maranta; Sara Bastian; Roger von Moos; Markus Joerger; Martin Früh

doi:10.1016/j.ejca.2024.113600

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Michael Mark, Patrizia Froesch, Katrin Gysel, Sacha I. Rothschild, Alfredo Addeo, Christoph J. Ackermann, Sabrina Chiquet, Martina Schneider, Karin Ribi, Angela Fischer Maranta, Sara Bastian, Roger von Moos, Markus Joerger, Martin Früh

Careum School of Health

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	113600
Number of pages	1
Journal	European Journal of Cancer
Volume	200
DOIs	https://doi.org/10.1016/j.ejca.2024.113600
Publication status	Published - 1 Mar 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2024.113600

http://dx.doi.org/10.1016/j.ejca.2024.113600

Cite this

Mark, M., Froesch, P., Gysel, K., Rothschild, S. I., Addeo, A., Ackermann, C. J., Chiquet, S., Schneider, M., Ribi, K., Maranta, A. F., Bastian, S., von Moos, R., Joerger, M., & Früh, M. (2024). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. European Journal of Cancer, 200, 113600. https://doi.org/10.1016/j.ejca.2024.113600

@article{55012701d44e438eb55763d51b857979,

title = "First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17",

author = "Michael Mark and Patrizia Froesch and Katrin Gysel and Rothschild, {Sacha I.} and Alfredo Addeo and Ackermann, {Christoph J.} and Sabrina Chiquet and Martina Schneider and Karin Ribi and Maranta, {Angela Fischer} and Sara Bastian and {von Moos}, Roger and Markus Joerger and Martin Fr{\"u}h",

year = "2024",

month = mar,

day = "1",

doi = "10.1016/j.ejca.2024.113600",

language = "English",

volume = "200",

pages = "113600",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Mark, M, Froesch, P, Gysel, K, Rothschild, SI, Addeo, A, Ackermann, CJ, Chiquet, S, Schneider, M, Ribi, K, Maranta, AF, Bastian, S, von Moos, R, Joerger, M & Früh, M 2024, 'First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17', European Journal of Cancer, vol. 200, pp. 113600. https://doi.org/10.1016/j.ejca.2024.113600

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. / Mark, Michael; Froesch, Patrizia; Gysel, Katrin et al.
In: European Journal of Cancer, Vol. 200, 01.03.2024, p. 113600.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

AU - Mark, Michael

AU - Froesch, Patrizia

AU - Gysel, Katrin

AU - Rothschild, Sacha I.

AU - Addeo, Alfredo

AU - Ackermann, Christoph J.

AU - Chiquet, Sabrina

AU - Schneider, Martina

AU - Ribi, Karin

AU - Maranta, Angela Fischer

AU - Bastian, Sara

AU - von Moos, Roger

AU - Joerger, Markus

AU - Früh, Martin

PY - 2024/3/1

Y1 - 2024/3/1

U2 - 10.1016/j.ejca.2024.113600

DO - 10.1016/j.ejca.2024.113600

M3 - Article

SN - 0959-8049

VL - 200

SP - 113600

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -